Earnings summaries and quarterly performance for Enveric Biosciences.
Executive leadership at Enveric Biosciences.
Board of directors at Enveric Biosciences.
Research analysts covering Enveric Biosciences.
Recent press releases and 8-K filings for ENVB.
Enveric Biosciences Expands Collaboration with TOTEC Pharma
ENVB
New Projects/Investments
- Enveric Biosciences' subsidiary, Akos Biosciences, has licensed its US Trademark portfolio for RCANN™ and an RCANN™ design to TOTEC Pharma, Inc.
- TOTEC Pharma is advancing the commercialization of patented cannabinoid crème technology created by Enveric, intended for the treatment of radiation dermatitis.
- The trademark license includes an option for TOTEC to purchase the RCANN trademark portfolio in the future, contingent on meeting certain development and commercialization milestones.
- Enveric's CEO, Joseph Tucker, stated that this license enhances the value of the previously licensed cannabinoid technology and extends Enveric's business development momentum by out-licensing non-core assets.
- The previously announced technology licensing agreement with TOTEC's affiliate, Aries, could generate significant milestone and royalty payments for Enveric if TOTEC's products are successful.
Jan 29, 2026, 1:00 PM
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering
ENVB
- Enveric Biosciences, Inc. announced the closing of a registered direct offering and concurrent private placement on January 28, 2026.
- In the registered direct offering, the company sold 328,802 shares of common stock at $4.41 per share, generating approximately $1.5 million in gross proceeds.
- Concurrently, a private placement involved the issuance of unregistered Series G and Series H warrants, each to purchase up to 328,802 shares of common stock at an exercise price of $4.16 per share.
- The estimated net proceeds of approximately $1.25 million from the offerings are intended for product development, working capital, and general corporate purposes.
Jan 28, 2026, 10:00 PM
Enveric Biosciences Closes $1.5 Million Registered Direct Offering
ENVB
- Enveric Biosciences (ENVB) announced the closing of a registered direct offering for the purchase and sale of 328,802 shares of common stock at a price of $4.41 per share.
- The offering generated approximately $1.5 million in gross proceeds for the company.
- Concurrently, Enveric issued unregistered series G and H warrants, each to purchase up to 328,802 shares of common stock, with an exercise price of $4.16 per share.
- The net proceeds from the offering are designated for product development, working capital, and general corporate purposes.
Jan 28, 2026, 10:00 PM
Enveric Biosciences Announces Registered Direct Offering
ENVB
- Enveric Biosciences announced a registered direct offering for the purchase and sale of 328,802 shares of common stock at a price of $4.41 per share.
- The offering is expected to generate approximately $1.5 million in gross proceeds.
- Concurrently, the company will issue unregistered series G and H warrants, each to purchase up to 328,802 shares of common stock at an exercise price of $4.16 per share.
- The net proceeds from the offering are intended for product development, working capital, and general corporate purposes.
Jan 28, 2026, 1:00 PM
Enveric Biosciences Announces New Patent Issuance
ENVB
New Projects/Investments
- Enveric Biosciences announced the issuance of U.S. Patent No. 12,492,179, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives,” on December 29, 2025.
- The patent covers novel molecules and methods of treatment for mental health disorders, expanding the company's pipeline of potentially neuroplastogenic and non-hallucinogenic molecules.
- This issuance strengthens Enveric's intellectual property protection and creates additional opportunities for licensing and partnerships with pharmaceutical companies in the neuropsychiatric field.
Dec 29, 2025, 1:00 PM
Enveric Biosciences Announces Warrant Exercise for $3.1 Million Gross Proceeds
ENVB
- Enveric Biosciences announced the immediate exercise of certain outstanding warrants, which is expected to generate approximately $3.1 million in gross proceeds for the company.
- The warrants, originally issued in February and September 2025 with exercise prices of $36.00 and $10.98 per share, respectively, were exercised at a reduced exercise price of $7.05 per share.
- In consideration for the immediate exercise, Enveric will issue new unregistered Series E and Series F warrants to purchase up to 426,390 shares of common stock each, both with an exercise price of $7.05 per share.
- The offering is expected to close on or about December 12, 2025, and the net proceeds will be used for product development, working capital, and general corporate purposes.
Dec 11, 2025, 6:43 PM
Enveric Biosciences Reports Q3 2025 Results and Corporate Updates
ENVB
Earnings
Delisting/Listing Issues
New Projects/Investments
- Enveric Biosciences reported a net loss of $3.4 million, or $10.81 per share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held $3.8 million in cash and cash equivalents and raised $7.9 million in net proceeds for the nine months ended September 30, 2025.
- The company continued to advance its lead candidate EB-003 towards clinical trials in 2026, receiving a positive FDA response to its pre-IND meeting request and completing key chemistry, manufacturing, and controls (CMC) milestones and dose range finding studies.
- Following a Nasdaq bid price deficiency delisting determination on October 22, 2025, Enveric Biosciences completed a reverse stock split on October 28, 2025, at a ratio of 1 post-split share for every 12 pre-split shares.
Nov 14, 2025, 9:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more